(Q41303102)

29 September 2017

1 reference

title

Molecular biology of plasminogen activators: what are the clinical implications of drug design? (English)

1 reference

29 September 2017

0 references

1 reference

R W Smalling

1

1 reference

29 September 2017

language of work or name

English

0 references

publication date

1 December 1996

1 reference

American Journal of Cardiology

29 September 2017

published in

1 reference

29 September 2017

volume

78

1 reference

29 September 2017

issue

12A

1 reference

29 September 2017

page(s)

2-7

1 reference

Beneficial effects of intracoronary thrombolysis up to eighteen hours after onset of pain in evolving myocardial infarction

29 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900736-9

Prehospital thrombolysis: beneficial effects of very early treatment on infarct size and left ventricular function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900736-9

Six- and twelve-month follow-up of the phase I Thrombolysis in Myocardial Infarction (TIMI) trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900736-9

Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900736-9

Effect of infarct artery patency on prognosis after acute myocardial infarction. The Survival and Ventricular Enlargement Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900736-9

TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction. Ventriculographic, enzymatic, and electrocardiographic evidence from the TEAM-3 Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900736-9

Impact of early perfusion status of the infarct-related artery on short-term mortality after thrombolysis for acute myocardial infarction: retrospective analysis of four German multicenter studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900736-9

The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900736-9

Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900736-9

A multicenter, randomized, placebo-controlled trial of a new form of intravenous recombinant tissue-type plasminogen activator (activase) in acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900736-9

Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900736-9

Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900736-9

Improved infarct-related arterial patency after high dose, weight-adjusted, rapid infusion of tissue-type plasminogen activator in myocardial infarction: results of a multicenter randomized trial of two dosage regimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900736-9

An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900736-9

Efficacy of 100 mg of double-bolus alteplase in achieving complete perfusion in the treatment of acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900736-9

A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900736-9

A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900736-9

Molecular biologic modification of plasminogen activators. An artful science

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900736-9

Towards better thrombolytic therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900736-9

Biochemical properties of the kringle 2 and protease domains are maintained in the refolded t-PA deletion variant BM 06.022

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900736-9

Coronary Thrombolytic Properties of a Novel Recombinant Plasminogen Activator (BM 06.022) in a Canine Model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900736-9

Evaluation of thrombolytic and systemic effects of the novel recombinant plasminogen activator BM 06.022 compared with alteplase, anistreplase, streptokinase and urokinase in a canine model of coronary artery thrombosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900736-9

Open, noncontrolled dose-finding study with a novel recombinant plasminogen activator (BM 06.022) given as a double bolus in patients with acute myocardial infarction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900736-9

Dose finding with a novel recombinant plasminogen activator (BM 06.022) in patients with acute myocardial infarction: results of the German Recombinant Plasminogen Activator Study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Kranken

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900736-9

A faster-acting and more potent form of tissue plasminogen activator

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900736-9

A long-half-life and fibrin-specific form of tissue plasminogen activator in rabbit models of embolic stroke and peripheral bleeding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900736-9

New Variant of Human Tissue Plasminogen Activator (TPA) With Enhanced Efficacy and Lower Incidence of Bleeding Compared With Recombinant Human TPA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900736-9

More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900736-9

Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900736-9

10.1016/S0002-9149(96)00736-9

7 January 2021

Identifiers

DOI

1 reference

29 September 2017

1 reference